Unknown NA INTERVENTIONAL 4-arm NCT03821701

Effect of Angiotensin-Neprilysin Inhibition (ARNI) on Prognosis of Chronic Heart Failure

A Multicenter, Randomized Controlled Trial of Angiotensin-Neprilysin Inhibition (ARNI) in the Chronic Heart Failure

Sponsor: Baoji Central Hospital

Updated 8 times since 2019 Last updated: Aug 5, 2019 Started: Jun 1, 2018 Primary completion: Jan 31, 2021 Completion: Jan 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Chronic Heart Failure, this trial is ongoing. The trial is conducted by Baoji Central Hospital and has accumulated 8 data snapshots since 2018. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

8 versions recorded

Apr 2025 — Present [monthly]

Unknown NA
Sep 2024 — Apr 2025 [monthly]

Unknown NA
Jul 2024 — Sep 2024 [monthly]

Unknown NA

Status: Unknown Status → Unknown
Mar 2022 — Jul 2024 [monthly]

Unknown Status NA

Status: Recruiting → Unknown Status
Jan 2021 — Mar 2022 [monthly]

Recruiting NA

▶ Show 3 earlier versions

Sep 2019 — Jan 2021 [monthly]

Recruiting NA
Mar 2019 — Sep 2019 [monthly]

Recruiting NA
Feb 2019 — Mar 2019 [monthly]

Recruiting NA

First recorded

Jun 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Baoji Central Hospital
First Affiliated Hospital Xi'an Jiaotong University

Data source: First Affiliated Hospital Xi'an Jiaotong University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Xi'an, China